Acute on chronic liver failure – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acute on chronic liver failure – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of VS-01 with different treatment times compared to standard care alone in patients with overt hepatic encephalopathy and liver cirrhosis complications https://clinicaltrials.eu/trial/study-of-vs-01-with-different-treatment-times-compared-to-standard-care-alone-in-patients-with-overt-hepatic-encephalopathy-and-liver-cirrhosis-complications/ Wed, 29 Apr 2026 15:06:50 +0000 https://clinicaltrials.eu/trial/study-of-vs-01-with-different-treatment-times-compared-to-standard-care-alone-in-patients-with-overt-hepatic-encephalopathy-and-liver-cirrhosis-complications/ This study focuses on patients with overt hepatic encephalopathy, a condition that affects brain function due to advanced liver disease. The condition occurs in people who have liver cirrhosis with sudden worsening of symptoms or acute complications. The study will test a new investigational medicine called VS-01, which is given as a suspension through the abdominal cavity, in addition to regular standard treatment.

The purpose of this research is to determine if VS-01 can help treat overt hepatic encephalopathy when given once daily for up to 4 days. The study will compare two different treatment durations (3 hours and 4 hours) of VS-01 combined with standard care against standard care alone. The medication contains citric acid as its main component and is administered through intraperitoneal delivery, which means it is given directly into the abdominal cavity.

During the study, patients will receive either VS-01 with standard treatment or standard treatment alone. The treatment period lasts up to 4 days, during which doctors will monitor how quickly patients’ symptoms improve. The study will also look at how the body processes the medication and track any changes in blood and abdominal fluid composition to ensure the treatment is safe.

]]> Study on the Effects of VS-01 for Adults with Acute-on-Chronic Liver Failure and Ascites https://clinicaltrials.eu/trial/study-on-the-effects-of-vs-01-for-adults-with-acute-on-chronic-liver-failure-and-ascites/ Wed, 29 Apr 2026 14:28:56 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-vs-01-for-adults-with-acute-on-chronic-liver-failure-and-ascites/ This clinical trial is focused on studying a condition known as acute-on-chronic liver failure (ACLF), which occurs when someone with long-term liver disease experiences a sudden worsening of their liver function. This can lead to problems with other organs and cause a buildup of harmful substances in the body, such as ammonia. This buildup can result in a condition called hepatic encephalopathy, which affects the brain and can lead to confusion and other mental changes. The trial is specifically looking at patients with ACLF grades 1 and 2 who also have a condition called ascites, where fluid accumulates in the abdomen.

The study is testing a new treatment called VS-01, which is given as a suspension for infusion directly into the abdominal cavity. The purpose of the study is to evaluate how effective, safe, and tolerable VS-01 is when used alongside the standard care that patients with ACLF already receive. Some patients will receive VS-01 in addition to their usual treatment, while others will continue with their standard care alone. The study will last for a short period, with the treatment being administered daily over four days.

Participants in the study will be monitored to see how their condition changes over time, with a particular focus on their CLIF-C ACLF score, which is a measure used to assess the severity of ACLF. The study will also look at other outcomes, such as survival rates and any side effects related to the treatment. The goal is to determine whether adding VS-01 to the standard care can improve outcomes for patients with ACLF and ascites.

]]> Study on the Safety and Effects of Resatorvid and Filgrastim for Patients with Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-resatorvid-and-filgrastim-for-patients-with-severe-alcoholic-hepatitis-and-acute-on-chronic-liver-failure/ Wed, 29 Apr 2026 14:24:40 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-resatorvid-and-filgrastim-for-patients-with-severe-alcoholic-hepatitis-and-acute-on-chronic-liver-failure/ This clinical trial is focused on studying two serious liver conditions: severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF). Severe alcoholic hepatitis is a condition caused by excessive alcohol consumption, leading to liver inflammation. Acute-on-chronic liver failure is a syndrome that occurs in patients with chronic liver disease, characterized by sudden liver failure and potentially affecting other organs like the kidneys and brain. The study will test the safety of a new treatment combining two medications: Resatorvid (TAK-242), which is a selective inhibitor of TLR4-mediated signaling, and Granulocyte Colony-Stimulating Factor (G-CSF), a substance that helps the body produce more white blood cells. A placebo will also be used for comparison.

The purpose of this study is to evaluate the safety of the combination treatment in patients with these liver conditions. Participants will receive either the combination of Resatorvid and G-CSF, Resatorvid alone, or a placebo. The treatment will be administered over a period of up to 10 days. The study will monitor the participants for any side effects and assess the impact of the treatment on liver function and overall health. The trial aims to understand how the treatment affects inflammation, liver function, and the body’s ability to recover from liver failure.

Throughout the study, researchers will collect data on various health markers, including inflammation and liver function, to determine the effectiveness of the treatment. The study will also look at the quality of life of participants and the number of days they spend in intensive care. The ultimate goal is to find a safe and effective treatment option for patients suffering from severe alcoholic hepatitis and acute-on-chronic liver failure.

]]>